R1 RCM Inc. (NASDAQ:RCM) to Post Q1 2024 Earnings of $0.02 Per Share, Leerink Partnrs Forecasts

R1 RCM Inc. (NASDAQ:RCM) – Equities researchers at Leerink Partnrs lowered their Q1 2024 earnings estimates for shares of R1 RCM in a report issued on Monday, April 29th. Leerink Partnrs analyst M. Cherny now forecasts that the healthcare provider will earn $0.02 per share for the quarter, down from their prior forecast of $0.03. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for R1 RCM’s current full-year earnings is ($0.05) per share. Leerink Partnrs also issued estimates for R1 RCM’s Q4 2024 earnings at $0.05 EPS and FY2026 earnings at $0.42 EPS.

Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of R1 RCM in a report on Wednesday, April 10th. Canaccord Genuity Group reduced their price objective on shares of R1 RCM from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, March 20th. Truist Financial reissued a “hold” rating and issued a $16.00 target price on shares of R1 RCM in a report on Monday, April 1st. Guggenheim lowered their price objective on R1 RCM from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, April 5th. Finally, Evercore ISI reissued an “in-line” rating and set a $16.00 target price (up previously from $12.00) on shares of R1 RCM in a research report on Wednesday, February 28th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, R1 RCM has a consensus rating of “Moderate Buy” and a consensus target price of $16.87.

R1 RCM Price Performance

Shares of NASDAQ RCM opened at $12.47 on Thursday. The business’s fifty day simple moving average is $12.95 and its 200-day simple moving average is $11.43. R1 RCM has a 12-month low of $8.87 and a 12-month high of $18.70. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.57.

Insider Activity at R1 RCM

In related news, President John M. Sparby sold 10,046 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $14.33, for a total value of $143,959.18. Following the transaction, the president now owns 265,986 shares in the company, valued at approximately $3,811,579.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 36.80% of the stock is owned by insiders.

Hedge Funds Weigh In On R1 RCM

A number of large investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in R1 RCM during the third quarter worth $36,000. ANTIPODES PARTNERS Ltd boosted its holdings in R1 RCM by 429.5% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock worth $59,000 after buying an additional 4,561 shares in the last quarter. Salem Investment Counselors Inc. acquired a new position in R1 RCM during the fourth quarter worth about $61,000. Van ECK Associates Corp increased its holdings in R1 RCM by 20.5% in the fourth quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock valued at $65,000 after buying an additional 1,044 shares in the last quarter. Finally, Caas Capital Management LP acquired a new stake in shares of R1 RCM during the 4th quarter valued at approximately $148,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.